Keywords: آگونیست دوپامین; PD; Parkinson's disease; NAS; Negative Affective Symptoms; DBS; Deep brain Stimulation; DA; Dopamine Agonist; LEDD; levodopa daily equivalent dose;
مقالات ISI آگونیست دوپامین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آگونیست دوپامین; Dopamine agonist; Estrus induction; Gonadotropin releasing hormone (GnRH) agonist;
Keywords: آگونیست دوپامین; Bromocriptine; Metformin; Prolactinoma; Refractory pituitary adenoma; AMPK; Adenosine monophosphate activated protein kinase; DA; Dopamine agonist; MRI; Magnetic resonance imaging; PRL; Prolactin;
Keywords: آگونیست دوپامین; Bromocriptine; cabergoline; dopamine agonist; hyperprolactinaemia; MRCP; prolactin; prolactinoma;
Keywords: آگونیست دوپامین; Prolactinoma; Infertility; Pregnancy; Dopamine agonist;
Keywords: آگونیست دوپامین; Parkinson disease; Dopamine agonist; Dopamine agonist withdrawal syndrome; Impulse control disorder;
Keywords: آگونیست دوپامین; Bone health; Hypogonadism; Men; Primary medical therapy; Primary surgical therapy; Prolactinoma; BMI; Body mass index; DA; Dopamine agonist; IQR; Interquartile ratio; PRL; Prolactin;
Keywords: آگونیست دوپامین; Restless legs syndrome; Willis-Ekbom disease; Sleep disorder; Adolescent; Periodic limb movements in sleep; Dopamine agonist;
Keywords: آگونیست دوپامین; Bromocriptine-QR; Dopamine agonist; Prolactin; Type 2 diabetes;
Keywords: آگونیست دوپامین; Neurodegeneration; Flavonoids; Antioxidant; Signalling pathways; Neuroinflammation; AD; Alzheimer's disease; PD; Parkinson's disease; HD; Huntington's disease; ALS; amyotrophic lateral sclerosis; MS; multiple sclerosis; DA; dopamine agonist; IFN; interfer
Keywords: آگونیست دوپامین; Parkinson's disease; Levodopa; Dopamine agonist; Monoamine oxidase B inhibitors; Cathecol-O-methyltransferase inhibitors; Anticholinergics; Amantadine;
Keywords: آگونیست دوپامین; Pathological gambling; Delay discounting; Parkinson disease; Restless legs syndrome; Impulse control disorder; Dopamine agonist; L-Dopa
Keywords: آگونیست دوپامین; Bromocriptine; Cabergoline; Dopamine agonist; Endoscopic endonasal transsphenoidal surgery; Pituitary tumor; Prolactinomas; Radiosurgery
Keywords: آگونیست دوپامین; Dopamine agonist; Parkinson disease; Impulse control disorder; Inhibition; Motor impulsivity; Reaction time;
Keywords: آگونیست دوپامین; Dopamine agonist; Intolerance; Prolactinoma; Resistance; Transsphenoidal surgery
Keywords: آگونیست دوپامین; Craniopharyngioma; Endoscopic surgery; Meningioma; Pituitary adenoma; Skull base; Transsphenoidal surgery; ACTH; adrenocorticotropic hormone; DA; dopamine agonist;
Keywords: آگونیست دوپامین; Restless legs syndrome; Augmentation; Dopamine agonist; Pramipexole; Ropinirole; Rotigotine; Methadone; Gabapentin;
Keywords: آگونیست دوپامین; Atypical adenoma; Prolactinoma; Intolerable severe headache; MiB-1 labeling index; Dopamine agonist
Keywords: آگونیست دوپامین; Parkinson's disease; Dopamine agonist; Apomorphine; Randomized controlled study;
Keywords: آگونیست دوپامین; Dopamine dysregulation syndrome; Dopamine agonist; 6-hydroxydopamine; Hemiparkinsonian;
Keywords: آگونیست دوپامین; Brain injury; Bruxism; Pramipexole; Central pattern generators; Dopamine agonist;
Keywords: آگونیست دوپامین; Restless legs syndrome (RLS); Willis–Ekbom disease; Meta-analysis; Dopamine agonist; Anticonvulsant; α2δ Ligand; Iron; Opioid; Treatment; Quality of life; Depression
Keywords: آگونیست دوپامین; Dopamine agonist; Elderly; Parkinson's disease; Rotigotine; Safety;
Keywords: آگونیست دوپامین; Dopamine agonist; Rotigotine; Restless legs syndrome; Transdermal delivery; Clinical practice; RLS-6;
Keywords: آگونیست دوپامین; Apomorphine; Acid-catalyzed rearrangement; Dopamine agonist; Dopamine D1 and D2 receptors; Morphinandiene;
Keywords: آگونیست دوپامین; Parkinson's disease; Early-onset; Impulse control behavior; Impulse control disorders; Dopamine agonist; Quality of life
Motor fluctuations and levodopa-induced dyskinesias in dopa-responsive dystonia
Keywords: آگونیست دوپامین; Levodopa; l-dopa; Dopamine-induced dyskinesia; Dyskinesia; DRD; Dopa-responsive dystonia; Dopamine; Dopamine agonist; Carbidopa-levodopa; Ropinirole; Wearing off phenomenon; DYT5; Motor fluctuation; GCH-1;
Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease
Keywords: آگونیست دوپامین; Iontophoresis; Transdermal; Dopamine agonist; MAO-B inhibitor; Patient compliance;
Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission
Keywords: آگونیست دوپامین; Atypical prolactinoma; Chemotherapy; Dopamine agonist; Invasive adenoma; Pituitary adenoma; Refractory prolactinoma; Temozolomide; DA; Dopamine agonist; MRI; Magnetic resonance imaging; SRS; Stereotactic radiosurgery; TMZ; Temozolomide;
Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese Subjects
Keywords: آگونیست دوپامین; bioequivalence; Chinese; dopamine agonist; pharmacokinetics; rotigotine; tolerability; transdermal delivery;
Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center
Keywords: آگونیست دوپامین; PD; Parkinson Disease; DAWS; dopamine agonist withdrawal syndrome; ICD; impulse control behavioral disorders; LEDD; levodopa equivalent daily dose; KP; Knowledge Program; HSM; health status measures; PHQ9; Patient Health Questionairre-9; GAD7; Generalized
Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial
Keywords: آگونیست دوپامین; Chronic kidney disease (CKD); dopamine agonist; rotigotine; restless legs syndrome (RLS); periodic limb movements (PLM); periodic limb movement index (PLMI); hemodialysis; end-stage renal disease (ESRD); randomized controlled trial (RCT);
Pramipexole for Chinese people with primary restless legs syndrome: a 12-week multicenter, randomized, double-blind study
Keywords: آگونیست دوپامین; Pramipexole; Sleep; Restless legs syndrome; Randomized controlled trial; Clinical trial; Dopamine agonist;
The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets
Keywords: آگونیست دوپامین; Istradefylline (PubChem CID: 5311037); Ropinirole HCl (PubChem CID: 68727); Pergolide mesylate (PubChem CID: 47812); Anti-parkinsonian; Adenosine A2A receptor antagonist; Dopamine agonist; MPTP;
Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: A non-interventional prospective multicenter trial
Keywords: آگونیست دوپامین; Dopamine agonist; Gastrointestinal; Non-motor; Parkinson's disease; Rotigotine;
The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets
Keywords: آگونیست دوپامین; Istradefylline (PubChem CID: 5311037); L-DOPA (PubChem CID: 6047); ropinirole HCl (PubChem CID: 68727); pergolide mesylate (PubChem CID: 47812)Anti-parkinsonian; Adenosine A2A receptor antagonist; L-DOPA; Dopamine agonist; MPTP
Sternberg working memory performance following treatment with pramipexole in patients with moderate-to-severe restless legs syndrome
Keywords: آگونیست دوپامین; Restless legs syndrome; Working memory; Dopamine agonist; Pramipexole; Event-related potential; P300;
Postencephalitic parkinsonism responsive to a dopamine agonist: A case report
Keywords: آگونیست دوپامین; Parkinsonism; Postencephalitic parkinsonism; Tick-borne encephalitis; Dopamine agonist; Pramipexole;
Selective multifaceted E3 ubiquitin ligases barricade extreme defense: Potential therapeutic targets for neurodegeneration and ageing
Keywords: آگونیست دوپامین; AAD; active adenylation domain; 4-PBA; 4-phenylbutyric acid; 6-OHDA; 6-hydroxydopamine; ABCG5/8; ATP-binding cassette sub-family G member 5/8; AD; Alzheimer's disease; AIB1; amplified in breast cancer 1; AIP4; atrophin-1 interacting protein 4; AMPA; α-
Ropinirole treatment in Parkinson's disease associated with higher serum level of inflammatory biomarker NT-proCNP
Keywords: آگونیست دوپامین; Parkinson's disease; CNP; Dopamine agonist; Inflammatory; Biomarker;
Reinforcing properties of Pramipexole in normal and parkinsonian rats
Keywords: آگونیست دوپامین; Parkinson's disease; Dopamine agonist; D2/3 agonist; Dopamine replacement therapy; 6-OHDA;
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats
Keywords: آگونیست دوپامین; Rotigotine-loaded microspheres; Subchronic toxicity; Sustained-release; Continuous dopaminergic stimulation; Dopamine agonist; Parkinson's disease;
Pituitary apoplexy associated with cabergoline therapy
Keywords: آگونیست دوپامین; Bromocriptine; Cabergoline; Dopamine agonist; Pituitary apoplexy; Prolactinoma
Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry
Keywords: آگونیست دوپامین; Dopamine; Dopamine agonist; Neurodegeneration; Neuroregeneration; Neuroimaging; Parkinson disease
Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness
Keywords: آگونیست دوپامین; PA; pituitary adenomas; PTTG; pituitary tumor transforming gene; IGF1R; insulin-like growth factor 1 receptor; RT-PCR; real time polymerase chain reaction; PI3K/Akt; phosphoinositide 3-kinase/Akt pathway; MAPK; mitogen-activated protein kinases; MRI; magn
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys
Keywords: آگونیست دوپامین; Rotigotine-loaded microspheres; Subchronic toxicity; Sustained-release; Continuous dopaminergic stimulation; Dopamine agonist; Parkinson’s disease
Ropinirole in Patients With Restless Legs Syndrome and Baseline IRLS Total Scores ≥24: Efficacy and Tolerability in a 26-Week, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by a 40-Week Open-Label Extension
Keywords: آگونیست دوپامین; clinical trial; dopamine agonist; restless legs syndrome; ropinirole
Evaluation of oral iron treatment in pediatric restless legs syndrome (RLS)
Keywords: آگونیست دوپامین; Restless legs syndrome; Children; Ferritin; Iron; Dopamine agonist; Japanese
Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study
Keywords: آگونیست دوپامین; OHSS; Dopamine agonist; RCT; Cabergoline;
Gender differences in the effects of presynaptic and postsynaptic dopamine agonists on latent inhibition in rats
Keywords: آگونیست دوپامین; Gender; Dopamine agonist; Latent inhibition; Sexual dimorphism